Harbour BioMed has bought an Atlas Venture-backed antibody player to further its ambition to build a pipeline of immuno-oncology programs. The deal sees Chinese VCs teaming with Big Pharma veterans to gain control of transgenic mouse platforms developed and commercialized in Cambridge, Massachusetts, and Rotterdam, the Netherlands.